About Xcell Biosciences
Xcell Biosciences is a company based in San Francisco (United States) founded in 2012. Xcell Biosciences has raised $40.9 million across 4 funding rounds from investors including Illumina, LabCorp and Casdin Capital. The company has 11 employees. Xcell Biosciences offers products and services including AVATAR Foundry, AVATAR Odyssey, and AVATAR AI. Xcell Biosciences operates in a competitive market with competitors including 10X Genomics, Denali Therapeutics, Poseida Therapeutics, Castle Biosciences and Juno Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 11
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website xcellbio.com
- Social LinkedIn X Facebook
- Legal Name Xcell Biosciences Inc.
- Total Equity Funding$40.9M (USD)
in 4 rounds
- Latest Funding Round$1.4M (USD), Series B
Dec 2024
- InvestorsIllumina
& 6 more
- Employee Count11
Products & Services of Xcell Biosciences
Xcell Biosciences offers a comprehensive portfolio of products and services, including AVATAR Foundry, AVATAR Odyssey, and AVATAR AI.
Scalable platform for cell therapy manufacturing in tumor environments.
Platform for cell therapy research and preclinical applications.
Tool to measure and enhance cell therapy potency effectively.
Funding Insights of Xcell Biosciences
Xcell Biosciences has successfully raised a total of $40.9M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $1.4 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40.9M
- Total Rounds 4
- Last Round Series B — $1.4M
- Investors Count 7
All 4 funding rounds of Xcell Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $1.4M | Series B | – | – | – |
| Jan 2022 | $27.5M | Series B | – | Casdin Capital | |
| Feb 2017 | $12M | Series A | – | HBM Genomics | – |
| Jul 2015 | – | Seed | – | – |
7 investors in total: 7 institutional.
Investors in Xcell Biosciences
Xcell Biosciences has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Illumina, LabCorp and Casdin Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investing in Life Sciences sectors like Healthcare and Biotechnology. | – | casdincapital.com | - | |
Investment in life sciences innovation is facilitated by Dynamk Capital. | – | dynamk.vc | New York, United States | |
Investments in early-stage biotech startups are made by Formic Ventures. | – | formic.vc | San Francisco, United States | |
Early-stage investments in healthcare sectors are targeted by HBM Genomics. | – | hbmgenomics.com | Palo Alto, United States | |
Private investment firm focused on multiple sectors | – | vikingglobal.com | Greenwich, United States | |
Provider of laboratory tests for physicians | 1969 | labcorp.com | Burlington, United States | |
Developer of technologies for analysis of genetic variation and function | 1993 | illumina.com | San Diego, United States |
Investor details for Xcell Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Xcell Biosciences
17 people are tracked at Xcell Biosciences (10 in leadership, 7 in team); the tracked headcount is 11.
| Name | Role | Group |
|---|---|---|
Hadia L. | Director Of Process Development | Leadership |
Brian Feth | CEO | Leadership |
Eric Choi | Director of Operations | Leadership |
Meri Meri | Director of Operations | Leadership |
Shannon Eaker | Chief Technology Officer | Leadership |
James Lim | Chief Scientific Officer | Leadership |
Vince So | Vice President, Product Development & Engineering | Leadership |
Candy Garcia | Sr Director Of R&d | Leadership |
Yelena Bronevetsky, PhD | Director, Product Management | Leadership |
David Cohen | Director of Intellectual Property | Leadership |
Evan Massi | Senior Scientist | Team |
Albert Wong | Scientist | Team |
Giaccomo Rischmoller | Engineering Technician | Team |
Gerardo Henriquez | Engineering Technician | Team |
Thomas Sullivan | Mechanical Engineer | Team |
Mark Muendelein | Mechanical Design Engineer | Team |
Adriana Marble | Mechanical Engineer | Team |
Complete people profiles for Xcell Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Xcell Biosciences
3 dated milestones of Xcell Biosciences across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Xcell Biosciences is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $1.4M.
Competitors of Xcell Biosciences
Xcell Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Denali Therapeutics, Poseida Therapeutics, Castle Biosciences and Juno Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| 10xgenomics.com | 2012 | Pleasanton, United States | $199.9M | 961 | Instrument systems for genomic research and sequencing libraries are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | |
| personalis.com | 2011 | Menlo Park, United States | $87.3M | 310 | Genomic sequencing and diagnosis software is provided for healthcare. | |
| unitybiotechnology.com | 2016 | San Francisco, United States | $206M | – | Therapeutics for aging diseases are developed by targeting senescent cells. | |
| unilabs.com | 2000 | Geneva, Switzerland | – | – | Diagnostic services are provided through laboratories and radiology units. | |
| missionbio.com | 2014 | San Francisco, United States | $110M | 109 | Single-cell multi-omics platform is provided for genotypic and phenotypic analysis. |
Detailed competitors of Xcell Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Xcell Biosciences
The website of Xcell Biosciences (xcellbio.com) receives about 4.4K visits a month.
- Monthly visits4.4K
▲ 20.6% vs previous month
Websites whose visitors overlap most with Xcell Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| emerypharma.com | 100% | 19.2K | #1,427,421 | View details | |
| atomwise.com | 98% | 3.8K | #4,893,237 | View details | |
| tempobioscience.com | 89% | 6.1K | #3,342,449 | View details | |
| gene.com | 48% | 492.6K | #97,838 | View details | |
| synthexlabs.com | 31% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 32 similar websites and full traffic analytics for Xcell Biosciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 32 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Xcell Biosciences
Complete news archive for Xcell Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Xcell Biosciences
10 companies that operate in the same segment as Xcell Biosciences (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Xcell Biosciences
Xcell Biosciences was founded in 2012 and raised its 1st funding round 3 years after it was founded.
Xcell Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Xcell Biosciences is a funded company, having raised a total of $40.9M across 4 funding rounds to date.
Xcell Biosciences has 11 employees.
Xcell Biosciences was founded in 2012 in San Francisco, United States, focusing on biotechnology for cancer research. A platform technology named Avatar is utilized to replicate in vivo conditions, enabling reproducible in vitro testing. Circulating tumor cells from patient blood are isolated and expanded through this system. Complementary cell-binding substrates and culture media are supplied. An AI-enabled tool is provided for real-time assessment of cell health, kinetics, and immunotherapy targets.
Xcell Biosciences's top competitors include Juno Therapeutics, 10X Genomics and Personalis.
Xcell Biosciences offers AVATAR Foundry, AVATAR Odyssey, and AVATAR AI.
Xcell Biosciences has 7 investors. Key investors include Illumina, LabCorp, Casdin Capital, Dynamk Capital, and Formic Ventures.
Xcell Biosciences operates through Xcell Biosciences Inc..